Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2 broadly neutralizing antibody (bnAbs), no plasma bnAb...

Full description

Bibliographic Details
Main Authors: David Easterhoff, M Anthony Moody, Daniela Fera, Hao Cheng, Margaret Ackerman, Kevin Wiehe, Kevin O Saunders, Justin Pollara, Nathan Vandergrift, Rob Parks, Jerome Kim, Nelson L Michael, Robert J O'Connell, Jean-Louis Excler, Merlin L Robb, Sandhya Vasan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, Sorachai Nitayaphan, Faruk Sinangil, James Tartaglia, Sanjay Phogat, Thomas B Kepler, S Munir Alam, Hua-Xin Liao, Guido Ferrari, Michael S Seaman, David C Montefiori, Georgia D Tomaras, Stephen C Harrison, Barton F Haynes
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-02-01
Series:PLoS Pathogens
Online Access:http://europepmc.org/articles/PMC5342261?pdf=render

Internet

http://europepmc.org/articles/PMC5342261?pdf=render

Similar Items